HK1094530A1 - N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt - Google Patents

N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Info

Publication number
HK1094530A1
HK1094530A1 HK07101468.4A HK07101468A HK1094530A1 HK 1094530 A1 HK1094530 A1 HK 1094530A1 HK 07101468 A HK07101468 A HK 07101468A HK 1094530 A1 HK1094530 A1 HK 1094530A1
Authority
HK
Hong Kong
Prior art keywords
benzamidine
pentoxy
thiazol
phenoxy
isopropyl
Prior art date
Application number
HK07101468.4A
Other languages
English (en)
Inventor
Jei Man Ryu
Jin Soo Lee
Dong Hyuk Shin
Seung Kyoo Seong
Soon Ki Cho
Chan Seok Jeon
Young Goo Jin
Ki Young Lee
Se Hyun Jung
Eun Hee Cho
Seok Hoon Ahn
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1094530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of HK1094530A1 publication Critical patent/HK1094530A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HK07101468.4A 2004-11-23 2007-02-08 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt HK1094530A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040096390 2004-11-23
PCT/KR2005/003934 WO2006057501A1 (en) 2004-11-23 2005-11-22 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Publications (1)

Publication Number Publication Date
HK1094530A1 true HK1094530A1 (en) 2007-04-04

Family

ID=36498212

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07101468.4A HK1094530A1 (en) 2004-11-23 2007-02-08 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Country Status (19)

Country Link
US (2) US20090176846A1 (xx)
EP (2) EP1701722B1 (xx)
JP (2) JP4774053B2 (xx)
KR (2) KR100716389B1 (xx)
CN (3) CN1905871B (xx)
AT (1) ATE445397T1 (xx)
AU (2) AU2005307994B2 (xx)
BR (2) BRPI0514386B8 (xx)
CA (2) CA2552766C (xx)
DE (1) DE602005017118D1 (xx)
DK (1) DK1701722T3 (xx)
ES (1) ES2333739T3 (xx)
HK (1) HK1094530A1 (xx)
IL (2) IL180985A (xx)
NZ (1) NZ555725A (xx)
PT (1) PT1701722E (xx)
RU (1) RU2361867C2 (xx)
WO (2) WO2006057507A1 (xx)
ZA (2) ZA200700485B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572898C (en) * 2004-07-05 2010-04-20 Dong Wha Pharmaceutical Ind. Co., Ltd. Composition for the prevention and treatment of allergic inflammatory disease
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
DK1701722T3 (da) * 2004-11-23 2010-01-11 Dong Wha Pharm Co Ltd N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt
MX2009010339A (es) * 2007-04-19 2009-10-16 Dong Wha Pharm Co Ltd Sal del acido 2-etanosulfonico de n-hidroxi-4{5-[4-(5-isopropil-2- metil-1,3-tiazol-4-il)fenoxi]pentoxi} benzamidina, procedimiento para su preparacion, y composicion farmaceutica que comprende la misma.
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
HUE042611T2 (hu) 2011-07-28 2019-07-29 Rigel Pharmaceuticals Inc Új (trimetoxifenilamino)pirimidinil készítmények
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN107530342A (zh) 2015-04-28 2018-01-02 安斯泰来制药有限公司 口服给药用医药组合物
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
US12083227B2 (en) 2017-08-18 2024-09-10 Abbvie Inc. Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
EA202090461A1 (ru) 2017-08-18 2020-06-29 Эббви Инк. Фармацевтические препараты для лечения эндометриоза, миомы матки, синдрома поликистоза яичников или аденомиоза
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
EP0379579A4 (en) * 1988-02-03 1991-01-02 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
US5914329A (en) * 1996-11-26 1999-06-22 Pfizer Inc. Dimesylate salts of neuropeptide Y ligands
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
RU2222529C2 (ru) * 1999-10-28 2004-01-27 Санкио Компани, Лимитед Производные бензамидина
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
AU2003219999A1 (en) * 2002-03-06 2003-09-22 Lifizz, Inc. Effervescent compositions comprising bisphosphonates and methods related thereto
BR0309188A (pt) * 2002-04-12 2005-02-09 Pfizer Compostos pirazolo como agentes antiinflamatórios e analgésicos
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
CN100342860C (zh) * 2003-03-18 2007-10-17 兴和株式会社 抗酸剂组合物
DK1701722T3 (da) * 2004-11-23 2010-01-11 Dong Wha Pharm Co Ltd N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt

Also Published As

Publication number Publication date
KR101047042B1 (ko) 2011-07-06
CN101056658A (zh) 2007-10-17
KR100716389B1 (ko) 2007-05-11
ATE445397T1 (de) 2009-10-15
IL180985A0 (en) 2007-07-04
AU2005300239A1 (en) 2006-07-06
DK1701722T3 (da) 2010-01-11
US20070254930A1 (en) 2007-11-01
ZA200700485B (en) 2007-11-28
ZA200704236B (en) 2008-11-26
CN1905871B (zh) 2010-07-07
EP1701722A1 (en) 2006-09-20
WO2006057507A1 (en) 2006-06-01
EP1701722A4 (en) 2007-05-16
IL180985A (en) 2012-02-29
EP1814593A1 (en) 2007-08-08
EP1701722B1 (en) 2009-10-14
DE602005017118D1 (de) 2009-11-26
CN101693029B (zh) 2011-11-02
AU2005300239B2 (en) 2009-08-06
KR20060057511A (ko) 2006-05-26
CN101693029A (zh) 2010-04-14
IL182647A (en) 2011-04-28
CN100574756C (zh) 2009-12-30
BRPI0517396A (pt) 2008-10-14
CA2585003C (en) 2010-08-17
JP2008508264A (ja) 2008-03-21
CA2585003A1 (en) 2006-06-01
CN1905871A (zh) 2007-01-31
WO2006057501A1 (en) 2006-06-01
BRPI0514386B1 (pt) 2021-02-09
BRPI0514386A (pt) 2008-06-10
CA2552766C (en) 2010-08-17
JP4773456B2 (ja) 2011-09-14
PT1701722E (pt) 2009-12-10
RU2007123614A (ru) 2008-12-27
JP4774053B2 (ja) 2011-09-14
AU2005307994B2 (en) 2009-07-23
RU2361867C2 (ru) 2009-07-20
CA2552766A1 (en) 2006-06-01
AU2005307994A1 (en) 2006-06-01
NZ555725A (en) 2008-07-31
KR20060057514A (ko) 2006-05-26
BRPI0514386B8 (pt) 2021-05-25
EP1814593A4 (en) 2012-09-05
ES2333739T3 (es) 2010-02-26
JP2008520655A (ja) 2008-06-19
US20090176846A1 (en) 2009-07-09
IL182647A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
HK1094530A1 (en) N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt
WO2003097622A3 (en) Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof
WO2009025983A3 (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
UA92354C2 (xx) Амінокислі солі росиглітазону$аминокислые соли росиглитазона
WO2008126899A1 (ja) 5員環へテロ環誘導体及びその医薬用途
WO2006003471A3 (en) Process for the preparation of pramipexole by chiral chromatography
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
EP1541570A4 (en) NEW PHYSIOLOGICALLY ACTIVE SUBSTANCE
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
WO2008133128A1 (ja) 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes
GB0410013D0 (en) Process
WO2009012201A3 (en) Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
WO2005012273A3 (en) Process for the preparation of substituted thiazoles
EP2146974A4 (en) SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT
WO2009069311A1 (ja) 3-メルカプトアニリン化合物の製造法
WO2005021542A3 (en) Process for the preparation of pioglitazone
WO2006021654A8 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
WO2008010089A3 (en) Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof
AU2003269479A1 (en) Phosphoric acid salt of 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) methyl)-2, 4-thiazolidinedione